| | Volume 1 Issue 2 |
| | Comment |
|
|
|
The cycle of genome-directed medicine
Janet
A
Buchanan,
Andrew
R
Carson,
David
Chitayat,
David
Malkin,
M Stephen
Meyn,
Peter
N
Ray,
Cheryl
Shuman,
Rosanna
Weksberg,
Stephen
W
Scherer
Genome Medicine 2009, 1:16 (2 February 2009)
Abstract |
Full text |
PDF
| PubMed
| Editor’s summary
Medical infrastructure needs to adapt to the dramatic pace of technology development in order for the cycle of genome-directed medicine to be complete.
|
|
|
|
Musings on genome medicine: abuse of genetic tests
David
G
Nathan,
Stuart
H
Orkin
Genome Medicine 2009, 1:18 (16 February 2009)
Abstract |
Full text |
PDF
| PubMed
| Editor’s summary
Developments in prenatal diagnostic testing for serious disorders have huge potential for medicine and public health, but the recent New York Times report of a gene test for athletic potential raises serious ethical questions.
|
|
|
|
Direct-to-consumer genetic tests: beyond medical regulation?
David
Magnus,
Mildred
K
Cho,
Robert
Cook-Deegan
Genome Medicine 2009, 1:17 (2 February 2009)
Abstract |
Full text |
PDF
| PubMed
| Editor’s summary
Personalized genomic tests provide a large amount of data but, because disease associations are weak for the vast majority of genetic loci, their interpretation remains problematic, raising questions over the need for stronger government regulation.
|
|
|
|
From association to causality: the new frontier for complex traits
Nicholas
Katsanis
Genome Medicine 2009, 1:23 (25 February 2009)
Abstract |
Full text |
PDF
| PubMed
| Editor’s summary
As genome-wide association studies rarely lead to the identification of causal alleles and therefore to the mechanisms that underlie disease; further efforts to evaluate the physiological impact of variation on gene function are needed.
|
|
|
|
Genomic medicine: considerations for health professionals and the public
Denise
Avard,
Bartha
Knoppers
Genome Medicine 2009, 1:25 (25 February 2009)
Abstract |
Full text |
PDF
| PubMed
| Editor’s summary
As advances in genomic medicine continue, the healthcare community must better understand how to incorporate genomics into delivery of care and must better communicate the risks and challenges of genomic information to the public.
|
|
|
|
Ancestry in translational genomic medicine: handle with care
David
Gurwitz,
Jeantine
E
Lunshof
Genome Medicine 2009, 1:24 (25 February 2009)
Abstract |
Full text |
PDF
| PubMed
| Editor’s summary
While personalized decision-making requires the combination of information about the population subgroup a person belongs to with information about the particular individual, genetic evidence should not be used to support policy guidelines that block access of individuals to healthcare based on ancestry.
|
| | Review |
|
|
|
Genome-based prediction of common diseases: methodological considerations for future research
A Cecile
JW
Janssens,
Cornelia
M
van Duijn
Genome Medicine 2009, 1:20 (18 February 2009)
Abstract |
Full text |
PDF
| PubMed
| Editor’s summary
A framework for the design and analysis of studies aiming to evaluate the clinical validity and utility of genetic tests is urgently needed to help identify useful genome-based applications for clinical and public health practice.
|
|
|
|
Gene-gene and gene-environment interactions: new insights into the prevention, detection and management of coronary artery disease
Matthew
B
Lanktree,
Robert
A
Hegele
Genome Medicine 2009, 1:28 (26 February 2009)
Abstract |
Full text |
PDF
| PubMed
| Editor’s summary
The study of gene-gene and gene-environment interactions will provide new insights into the determinants of coronary artery disease, though agreed standards of study design and statistical power, environmental exposure measurement, phenomic characterization and analytical strategies are needed.
|
|
|
|
Genome-wide association studies are coming for human infectious diseases
Sonia
Davila,
Martin
L
Hibberd
Genome Medicine 2009, 1:19 (10 February 2009)
Abstract |
Full text |
PDF
| PubMed
| Editor’s summary
The application of genome-wide association studies to human infectious diseases holds promise for the identification of polymorphisms affecting a large proportion of the population, and thus for improved prognosis and treatment.
|
|
|
|
A new, effective and high-yield approach for identifying liver tumor suppressors
Esra
Olgun,
Lewis
R
Roberts
Genome Medicine 2009, 1:26 (26 February 2009)
Abstract |
Full text |
PDF
| PubMed
| Editor’s summary
The combination of integrated cancer genomic analysis, RNAi technology and cancer-susceptible mouse models to discover and validate tumor suppressor genes provides novel insights into the development of hepatocellular carcinoma.
|
| | Report |
|
|
|
Copy number variation and genomic alterations in health and disease
George
P
Patrinos,
Michael
B
Petersen
Genome Medicine 2009, 1:21 (20 February 2009)
Abstract |
Full text |
PDF
| PubMed
| Editor’s summary
A report of the first Golden Helix Symposium on copy number variation and genomic alterations in health and disease.
|
|
|
|
Insights from Keystone: advances in the understanding of epigenetic regulation of the genome
Rebecca
C
Rancourt,
Nico
Ruf
Genome Medicine 2009, 1:27 (26 February 2009)
Abstract |
Full text |
PDF
| PubMed
| Editor’s summary
A report on the Keystone Symposium on Epigenetics, Development and Human Disease, Breckenridge, Colorado, USA, 5-10 January, 2009.
|
| | Correspondence |
|
|
|
Commercialization, patenting and genomics: researcher perspectives
CJ
Murdoch,
Timothy
Caulfield
Genome Medicine 2009, 1:22 (19 February 2009)
Abstract |
Full text |
PDF
| PubMed
| Editor’s summary
Genomic researchers have divided views regarding the effect of commercialization and patenting on research, and although publication delays and the withholding of data are common, the aggressive enforcement of patents is not.
|
